October 26, 2016

AbbVie’s Rova-T Wins ‘Most Promising Clinical Candidate’ Award

AbbVie’s Rova-T Wins ‘Most Promising Clinical Candidate’ Award award at World Antibody Drug Conjugate Summit.

Share to Facebook Share to Twitter Share to Linkedin Email Sign Up for Alerts Print
Scott Dylla, AbbVie Stemcentrx vice president and chief
scientific officer

The AbbVie Stemcentrx investigational asset known as “Rova-T” (rovalpituzumab tesirine) was recently recognized at the 7th Annual World Antibody Drug Conjugate (ADC) Awards as the “Most Promising Clinical Candidate” for fighting cancer tumors.

World ADC is considered the definitive forum for ADC thought leaders. The 7th Annual World ADC Summit gathered more than 650 colleagues and 90 ADC experts for 96 sessions on drug development, pre-clinical and clinical work and the latest intelligence in this area of oncology.

With the addition of Rova-T and additional early stage and pre-clinical assets, AbbVie’s oncology portfolio consists of marketed medicines and a robust pipeline of new molecules being evaluated worldwide in nearly 200 clinical trials in 20 different tumor types. 

AbbVie Stemcentrx also won the top prize at World ADC for “Best Publication,” and AbbVie Stemcentrx vice president and chief scientific officer Scott Dylla, Ph.D., was named runner-up for “Individual Input to the Field 2015/2016.”